NCT05295979CompletedPhase 2
Chinese Medicine for Patients With Psoriasis
Development of a Novel Chinese Medicine Formula for the Treatment of Psoriasis: A Randomized, Double-blinded, Placebo-controlled Trial
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
Psoriasis is an inflammatory skin disease with huge negative impact on the quality of life of the patients, and has an overall prevalence of 2% to 3% in the general population. Plaques psoriasis is the most common type of the disease and presents red, well demarcated, and silvery plaques mainly localized in the umbilical and lumbosacral area as well as in the elbows, knees, and scalp. Currently, pharmacological treatments such as retinoids, corticosteroids, vitamin D analogs and biologics remain the main options for most psoriasis patients. However, side effect and high cost barred many ordinary psoriasis patients. A Chinese medicine formula "Inflammatory skin disease formula (ISDF)" was prescribed by Prof. Lin for many years and observed to be effective in relieving atopic dermatitis and psoriasis patients' clinical manifestations. In this study, subjects with psoriasis will be randomized into treatment group of "ISDF" or placebo group for 12 weeks.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 24 Feb 2022
- Start date
- 20 Mar 2023
- Primary completion date
- 27 Mar 2026
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Psoriasis
- NCT number
- NCT05295979
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 60
- From 20 Mar 2023 to the primary completion date, 27 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Systemic therapy for psoriasis 6 months prior to baseline.
- Use topical medications for psoriasis 14 days prior to baseline such as retinoids, corticosteroids, vitamin D analogues, tazarotene and tacrolimus.
- Has taken any antibiotics, probiotics and prebiotics 30 days prior to baseline.
- UV light therapy 30 days prior to baseline.
Other illness
- Psoriatic arthritis with syndrome of spleen-kidney yang deficiency according to Chinese medicine theory.
- History of allergy to Chinese herbs.
- Any other condition that in the opinion of the investigators could compromise the study.
Lab values
- Clinically significant laboratory abnormality in blood, liver or renal functions (≥1.5 times the upper limit of reference range).
Other
- Pustular or generalized erythrodermic psoriasis.
- Unwillingness to comply with study protocol.
Who the study is looking for
- Mild to moderate chronic plaque psoriasis (PASI score 3 to 12).
- Willingness to give informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hong Kong Institute of Integrative Medicine Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.